Central to the research is the recognition that immune ageing, characterized by the progressive dysfunction and decline in immune cell performance, is a key factor leading to increased vulnerability in the elderly and those with chronic infections. T cells, particularly the CD4+ subtype—often regarded as the conductors of the immune orchestra—become less effective with time, diminishing the immune system’s ability to coordinate defenses accurately. These cells, rendered senescent or exhausted, exhibit impaired proliferation, cytokine production, and cytotoxic activity, undermining responses to pathogens, malignancies, and cellular damage.

The novel therapy, developed by SenTcell, a biotech startup founded by Dr. Alessio Lanna from UCL Medicine, employs a liquid formulation administered intramuscularly akin to conventional vaccines. This delivery method facilitates patient-friendly administration while targeting key metabolic pathways within dysfunctional T cells. By reprogramming the intracellular environment of these immune cells, the treatment aims to restore youthful functional properties, including enhanced proliferative capacity and efficient pathogen recognition, thereby revitalizing the immune system’s broad protective functions.

Dr. Lanna explains that although antiretroviral advancements have significantly improved lifespans for individuals living with HIV, many still experience premature immune ageing. Similar patterns of immune exhaustion are also detected in cancer patients and other chronic disease cohorts. The imminent clinical trial represents a critical stepping stone towards verifying whether exhausted immune cells can be safely and effectively rejuvenated in human subjects, with the potential to redefine therapeutic paradigms for diseases rooted in immune dysregulation.

At the molecular level, one of the intriguing aspects under investigation involves the role of telomeres—protective caps on chromosome ends whose shortening serves as a hallmark of biological ageing. Laboratory studies have suggested that rejuvenated CD4+ T cells may release telomere-containing extracellular structures, whimsically termed “telomere Rivers,” into the bloodstream. The presence and behavior of these structures might offer novel insights into how restored immune cells influence systemic health, extending their benefits beyond immediate immune niches to broader tissue health. Although this phenomenon has yet to be validated in human clinical contexts, it highlights the sophisticated interplay between immune rejuvenation and organismal aging.

The clinical trial enjoys regulatory support from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) through its Innovative Licensing and Access Pathway (ILAP), underscoring the therapy’s potential to meet the pressing unmet medical needs associated with immune senescence. This endorsement accelerates development timelines and affirms the significance of targeting immune metabolic dysfunction as a viable therapeutic strategy.

Participants in the upcoming Phase 1 trial will be meticulously selected adults exhibiting characteristics of immune dysfunction, including evidence of premature immune ageing or persistent viral infections. Comprehensive immune profiling will be conducted before and after therapeutic administration to discern immunological changes and safety outcomes. Although the initial focus is on evaluating biological activity and tolerability, successful results could pave the way for advanced trials assessing clinical efficacy.

Unlike conventional treatments that combat diseases by targeting individual pathogens or tumor cells directly, this therapy seeks to recalibrate the immune system itself—restoring its intrinsic resilience and regenerative functionality. Such a paradigm shift holds profound implications; by enhancing the immune system’s natural defensive repertoire, it may afford broad-spectrum protection and facilitate healthier ageing trajectories.

Beyond chronic infections like HIV and cancer, this approach could ultimately apply to autoimmune disorders characterized by immune exhaustion, wherein overly active yet dysfunctional immune cells drive pathology. Immune rejuvenation strategies offer a novel means of restoring balance without broadly suppressing immune activity, potentially mitigating disease progression while improving quality of life.

This research aligns with a growing global focus on understanding the cellular and molecular underpinnings of ageing and immune decline. By intervening at the level of T cell metabolism and function, scientists hope to extend not only lifespan but healthspan—preserving cognitive and physical function while reducing susceptibility to infections, cancer, and degenerative diseases.

As UCL celebrates two centuries of academic excellence and innovation, this project embodies the institution’s commitment to translating bold scientific ideas into therapies capable of reshaping medicine. If validated through clinical trials, this immune rejuvenation therapy could herald a transformative era in treating age-associated diseases, offering hope for millions affected by immune dysfunction worldwide.

Subject of Research: People
Article Title: Immune Rejuvenation: UCL’s Pioneering Trial Targets T Cell Exhaustion to Combat Age-Related Immune Decline
News Publication Date: Not provided
Web References: www.ucl.ac.uk
References: Not provided
Image Credits: Not provided
Keywords: Immune ageing, T cell exhaustion, CD4+ T cells, immune rejuvenation, senescent immune cells, telomeres, immune dysfunction, chronic disease, HIV, cancer, metabolic resetting, Phase 1 clinical trial

Parkinson’s disease is marked by the gradual death of dopamine-producing neurons within the substantia nigra, a brain region essential for regulating movement and coordination. For decades, the neurodegenerative cascade has been understood primarily in terms of intrinsic neuronal dysfunction and protein aggregation. However, mounting evidence points to the critical role of neuroinflammation—specifically, the immune activation of microglia—in exacerbating neuronal loss. This latest research elucidates the precise receptor-mediated mechanisms by which microglia actively dispose of dopaminergic neurons through phagocytosis.

Microglia possess multiple receptors through which they interact with their environment, but the Fc gamma receptors are unique in their ability to bind the Fc portion of immunoglobulin G (IgG) antibodies. While high-affinity FcγRs have been studied extensively in peripheral immune responses, microglial low-affinity FcγRs have remained poorly characterized in the context of neurodegeneration. Casanova and colleagues have now demonstrated that this subset of FcγRs mediates enhanced phagocytic activity directed against dopaminergic neurons marked for elimination during Parkinsonian degeneration.

Using sophisticated in vivo and in vitro models of Parkinson’s disease, the researchers employed genetic and pharmacological tools to selectively modulate low-affinity FcγRs activity. They observed that microglia expressing these receptors showed increased engulfment of dopaminergic neurons, correlating with accelerated neuronal death. Conversely, blocking the receptors mitigated phagocytic clearance and preserved neuronal numbers, highlighting the receptor’s pivotal role in driving disease progression.

At the molecular level, the activation of low-affinity FcγRs triggers a cascade of intracellular signaling pathways culminating in cytoskeletal reorganization and the formation of phagosomes. This process enables microglia to physically engulf and degrade neuronal debris or stressed neurons. Intriguingly, the study revealed that dopaminergic neurons under oxidative and proteostatic stress express ‘eat-me’ signals—such as altered surface proteins and exposed phosphatidylserine—that tag them for microglial recognition via FcγRs-mediated opsonization.

The identification of these ‘eat-me’ signals adds a layer of complexity to how neuronal demise is orchestrated in Parkinson’s disease. It appears that afflicted neurons inadvertently become immunologically marked by endogenous antibodies or other opsonins, which microglial low-affinity FcγRs recognize and bind. This interaction effectively bridges the immune and nervous systems, transforming microglia into executioners that eliminate neurons deemed dysfunctional or damaged.

Importantly, the study also provides insight into the temporal dynamics of microglial FcγR signaling during the disease course. Early-stage Parkinsonian brains exhibited heightened low-affinity FcγR expression and phagocytic activity before extensive neuronal loss was detectable. This suggests that microglial-mediated clearance is not merely a consequence of neuronal death but an active driver initiating the degenerative cycle.

From a therapeutic perspective, the findings open exciting avenues for intervention. By selectively targeting low-affinity FcγRs, it may be possible to temper microglial phagocytosis and preserve dopaminergic neurons without broadly suppressing the immune system. The study’s demonstration that pharmacological inhibitors of these receptors can attenuate neuron loss in animal models reinforces the translational potential of this strategy.

Beyond Parkinson’s disease, the implications of this work extend to other neurodegenerative disorders where microglia and aberrant phagocytosis contribute to pathology. Conditions such as Alzheimer’s disease, amyotrophic lateral sclerosis, and multiple sclerosis all involve complex immune-neuronal interactions, and FcγRs might represent a shared molecular target to modulate these interactions beneficially.

On a cellular scale, the study underscores the dualistic nature of microglia as both guardians and executioners of central nervous system integrity. While they are essential for maintaining homeostasis and clearing cellular debris, their activation via FcγRs in the context of chronic neurodegeneration paradoxically accelerates neuronal loss. Understanding this balance is pivotal for designing therapies that harness protective microglial functions while inhibiting deleterious ones.

Technically, the researchers employed state-of-the-art imaging techniques, including two-photon microscopy and fluorescence-activated cell sorting, to track FcγR expression and microglial-neuron interactions in real time. Coupled with single-cell RNA sequencing, this approach allowed precise characterization of microglial subpopulations with differential FcγR expression profiles, unveiling cellular heterogeneity linked to disease vulnerability.

Moreover, the team explored the downstream signaling molecules engaged upon FcγR activation, identifying key kinases and adaptor proteins that modulate actin polymerization and vesicle trafficking. These mechanistic insights pave the way for pharmacological modulation targeting specific intracellular nodes within the FcγR-driven phagocytosis pathway, potentially offering greater therapeutic specificity.

This comprehensive investigation also addressed how systemic inflammation and peripheral immune factors influence microglial FcγR-mediated clearance. By administering systemic inflammatory stimuli, the researchers observed exacerbated microglial activation and phagocytic activity via FcγRs, suggesting that peripheral immune challenges might accelerate Parkinsonian neurodegeneration through this axis.

Critically, the human relevance of these findings was validated by examining post-mortem brain tissue from Parkinson’s patients, where elevated expression of low-affinity FcγRs on microglia was observed in substantia nigra regions undergoing active neurodegeneration. These clinical correlations substantiate the translational applicability of modulating FcγR pathways in therapeutic development.

While these results represent a significant advance, the authors acknowledge that further studies are needed to fully delineate the interactions between antibodies, opsonins, and FcγRs in vivo. Additionally, understanding how aging and genetic risk factors influence microglial FcγR expression and function will be essential to optimize treatment timing and efficacy.

In sum, the pioneering work by Casanova et al. reveals that microglial low-affinity Fc gamma receptors act as critical mediators of dopaminergic neuron phagocytosis during Parkinson’s disease progression. By illuminating the immunological underpinnings of neuronal elimination, this study charts a path toward innovative immunomodulatory therapies that may one day transform the clinical management of Parkinson’s and related disorders.

Subject of Research: Mechanisms of microglial phagocytic elimination of dopaminergic neurons in Parkinson’s disease via low-affinity Fc gamma receptors.

Article Title: Microglial low-affinity FcγR mediates the phagocytic elimination of dopaminergic neurons in Parkinson’s disease degeneration.

Article References: Casanova, P.V., Freitag-Berenguel, I., Saavedra-López, E. et al. Microglial low-affinity FcγR mediates the phagocytic elimination of dopaminergic neurons in Parkinson’s disease degeneration. npj Parkinsons Dis. (2026). https://doi.org/10.1038/s41531-025-01249-9

Image Credits: AI Generated